DBV Technologies (NASDAQ:DBVT) Earns Hold Rating from Analysts at StockNews.com

StockNews.com began coverage on shares of DBV Technologies (NASDAQ:DBVT) in a research note issued to investors on Tuesday. The firm issued a hold rating on the stock.

Other equities research analysts also recently issued reports about the company. JMP Securities reissued a “market outperform” rating and issued a $10.00 target price on shares of DBV Technologies in a report on Friday, January 10th. HC Wainwright boosted their target price on DBV Technologies from $25.00 to $35.00 and gave the stock a “buy” rating in a report on Thursday, October 24th.

DBV Technologies Trading Down 4.1 %

DBV Technologies stock opened at $4.26 on Tuesday. The business’s fifty day simple moving average is $3.97 and its two-hundred day simple moving average is $3.84. DBV Technologies has a 12 month low of $2.20 and a 12 month high of $9.09. The company has a market capitalization of $87.63 million, a price-to-earnings ratio of -0.95 and a beta of 0.67.

Institutional Inflows and Outflows

A hedge fund recently bought a new stake in DBV Technologies stock. Boxer Capital Management LLC purchased a new position in DBV Technologies S.A. (NASDAQ:DBVT) during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm purchased 50,000 shares of the company’s stock, valued at approximately $154,000. Boxer Capital Management LLC owned 0.24% of DBV Technologies at the end of the most recent quarter. Institutional investors own 71.74% of the company’s stock.

DBV Technologies Company Profile

DBV Technologies SA, a clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products. Its product pipeline comprising Viaskin Peanut, an immunotherapy product, which has completed Phase 3 clinical trial for the treatment of peanut allergies; and Viaskin Milk which is in Phase 1/2 clinical trial for the treatment of immunoglobulin E (IgE) mediated or cow’s milk protein allergy and eosinophilic esophagitis.